Charles River Laboratories Inte
CRL Mid CapHealthcare · Diagnostics & Research
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Charles River Laboratories Inte en bref
Charles River Laboratories Inte (CRL) is currently trading at 161,28 € with a market capitalization of 7,8 Md €. The 52-week range spans from 125,76 € to 199,53 €; the current price is 19.2% below the yearly high. Year-over-year revenue growth stands at +1.2%.
💰 Dividende
Charles River Laboratories Inte currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
15 analystes évaluent Charles River Laboratories Inte (CRL) au consensus : Acheter. L'objectif de cours moyen est de 185,05 €, soit un potentiel de +14.74% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 117,69 € à 231,02 €.
Charles River Laboratories Inte : la thèse d'investissement en détail
Charles River Laboratories Inte (CRL) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario baissier
Revenue growth has slowed to just 1.2%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.
Valorisation en contexte
With a PEG ratio of 0.12, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.
Thèse d'investissement : forces et faiblesses
- Consensus des analystes : Buy
- Free cash flow positif
- –Actuellement non rentable
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to market-like volatility, elevated short interest (9.34%), higher leverage relative to equity.
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Charles River Laboratories Inte?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news